[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Weill Medical College of Cornell University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":670},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,154,0,25,[9,45,67,119,146,174,201,227,246,270,295,316,340,366,391,413,435,463,479,518,542,570,590,621,639],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100525226","improving-transitions-and-outcomes-for-heart-failure-patients-in-home-health-care-i-transfer-hf-100525226",false,"NCT06118983","Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)","Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF): A Type 1 Hybrid Effectiveness- Implementation Trial","Aim 1, Inclusion Criteria:\n\n* Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.\n\nAim 1, Exclusion Criteria:\n\n* Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.\n\nAim 2, Inclusion Criteria:\n\n\\- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.\n\nAim 2, Exclusion Criteria:\n\n\\- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.",true,"ALL","18 Years",{"count":21,"type":22},1094,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.\n\nThe study is interested in two questions:\n\n1. Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?\n2. Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?\n\nThe researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.",[28],"Heart Failure",[30,31],"home health care","hospital-to-home transition","RECRUITING","2026-08-19",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2026-07-28",{"date":40,"type":22},"2028-07-01",{"name":42,"class":43},"Weill Medical College of Cornell University","OTHER",2,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100484217","engage--connect-a-psychotherapy-for-postpartum-depression-100484217","NCT05585164","Engage & Connect: A Psychotherapy for Postpartum Depression","Engage & Connect: A Novel Social Reward Psychotherapy for Postpartum Depression","Inclusion Criteria:\n\n1. Up to 1 year post-delivery\n2. Edinburgh Postnatal Depression Scale (EPDS) score ≥ 10.\n3. Off antidepressants or on a stable dose of an antidepressant for 8 weeks and do not intend to change the dose in the next 10 weeks.\n4. Capacity to provide consent for research assessment and treatment.\n5. Speaks English proficiently\n\nExclusion Criteria:\n\n1. Intent or plan to attempt suicide in the near future\n2. Ongoing psychotherapy (no more than once every 8 weeks or during the duration of the intervention)\n3. Active substance abuse or dependence\n4. Severe fetal anomalies, stillbirth or infant death at time of enrollment for index pregnancy\n5. History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, persistent depressive disorder, or specific phobia.\n6. Use of psychotropic drugs or cholinesterase inhibitors other than use of ≤ 0.5 mg of lorazepam daily up to seven times per week.","FEMALE",{"count":54,"type":22},60,[25],"This randomized controlled trial compares a novel psychotherapy, Engage \\& Connect, with a Symptom Review and Psychoeducation intervention, tailored to reduce postpartum depression. The study includes 9-weeks interventions, delivered remotely. It will examine changes in social isolation, processing of social rewards and depression severity over 9 weeks of treatment.",[58],"Postpartum Depression",{"date":60,"type":36},"2026-08-20",{"date":62,"type":36},"2022-11-01",{"date":64,"type":22},"2030-07",{"name":42,"class":43},1,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":66},"100484214","phase-4-a-preliminary-study-for-informed-100484214","NCT05585125","A Preliminary Study for INFORMED","A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization","PRE-INFORMED","Inclusion Criteria:\n\n1. Ambulatory adults age ≥ 65 years with HFpEF, according to ACC\u002FAHA guidelines (signs and symptoms of heart failure AND ejection fraction ≥ 50%)\n2. Taking beta-blocker\n\nExclusion Criteria:\n\n1. Alternate cause(s) of HFpEF Syndrome:\n\n   1. Severe aortic stenosis\n   2. Moderate-severe mitral stenosis\n   3. Constrictive pericarditis\n   4. High output HF\n   5. Infiltrative cardiomyopathy\n2. Other compelling indication(s) for beta-blocker\n\n   1. Prior EF \\\u003C 50%\n   2. Hypertrophic cardiomyopathy\n   3. Angina\n   4. Acute coronary syndrome, myocardial infarction, or coronary artery bypass surgery in prior 3 years\n   5. History of ventricular tachycardia\u002Farrhythmia\n   6. Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year\n   7. Heart rate \\>100 bpm within the prior 3 months\n   8. Atrial arrhythmia with ventricular rate \\>90 per minute in the prior 3 months\n   9. Systolic blood pressure readings \\>160 mmHg within the prior 3 months, unless classified as white coat hypertension\u002Feffect (and home blood pressures below 140 mmHg)\n   10. Non-cardiac indications (e.g., migraine prevention, anxiety symptom management, hyperthyroidism, essential tumor reduction)\n3. Clinical instability (N-of-1 trials are appropriate for stable conditions only)\n\n   1. Decompensated heart failure\n   2. Hospitalization in the past 30 days\n   3. Medication changes or procedures in the prior 14 days that could confound observations\u002Fdata at PI discretion\n   4. Anticipated medication changes or procedures in subsequent 3 months that could confound observations\u002Fdata at PI discretion\n   5. Clinical instability from other medical issues\n4. Estimated life expectancy \\\u003C 6 months\n5. Moderate-severe dementia or psychiatric disorder precluding informed consent\n6. Language barrier that will preclude informed consent and ability to comprehend study procedures\n7. Non-compliance or inability to complete study procedures\n8. Enrollment in a clinical trial not approved for co-enrollment\n9. Any condition that, in the Principal Investigator or treating physician's opinion, makes the patient unsuitable for study participation","65 Years",{"count":77,"type":22},18,[79],"PHASE4","Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).",[28,82,83,84,85],"Heart Failure, Diastolic","Heart Failure With Preserved Ejection Fraction","Cardiac Failure","Heart Diseases",[87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112],"Propranolol","Metoprolol","Atenolol","Sotalol","Nadolol","Acebutolol","Carvedilol","Nebivolol","Bisoprolol","Labetalol","Pindolol","Betaxolol","Penbutolol","Adrenergic beta-Antagonists","Adrenergic Antagonists","Adrenergic Agents","Neurotransmitter Agents","Molecular Mechanisms of Pharmacological Action","Physiological Effects of Drugs","Anti-Arrhythmia Agents","Antihypertensive Agents","Vasodilator Agents","Sympatholytics","Autonomic Agents","Peripheral Nervous System Agents","Adrenergic beta-1 Receptor Antagonists",{"date":35,"type":36},{"date":115,"type":36},"2024-02-07",{"date":117,"type":22},"2027-11",{"name":42,"class":43},{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":66},"100647599","low-gas-pressure-vs-standard-gas-pressure-in-weight-loss-surgery-100647599","NCT07710352","Low Gas Pressure vs Standard Gas Pressure in Robotic Surgery","Comparison Between Low Pressure (8 mmHg) AirSeal Insufflation vs Standard Pressure (15 mmHg) Pneumoperitoneum on Postoperative Recovery in Minimally Invasive Robotic Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 years or older\n* Scheduled to undergo robotic-assisted surgery at New York-Presbyterian\u002FWeill Cornell Medical Center\n* American Society of Anesthesiologists physical status I-III\n* Able to understand and provide written informed consent in English\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists physical status IV or higher (i.e. a severe systemic disease that is a constant threat to life such as decompensated heart failure)\n* Chronic opioid use (≥30 morphine milligram equivalents per day for ≥30 days within the past 6 months)\n* Current pregnancy\n* Inability to understand and provide informed consent in English\n* Inability to provide informed consent due to cognitive impairment or other conditions impacting decision-making capacity\n* Scheduled open or laparoscopic surgeries",{"count":127,"type":22},100,[25],"During surgery that is done using a robot, the surgeon needs to put carbon dioxide gas into the belly to lift the belly wall. This is done so the surgeon can adequately see all the body organs and operate safely. Many surgeons currently use a standard pressure of 15 mmHg (a unit to measure pressure). However, many patients find the use of this pressure to be painful after surgery. New research has shown that using a lower pressure with a device called \"AirSeal\" can safely reduce pain and lead to faster recovery after surgery.\n\nThe goal of this clinical trial is to learn if using a lower gas pressure with the AirSeal device during robotic surgery, compared to standard gas pressure with conventional devices, helps adults feel less pain and recover faster.\n\nThe study includes adults aged 18 or older having robotic at New York-Presbyterian Hospital\u002FWeill Cornell Medical Center.\n\nThe main questions this clinical trial aims to answer are:\n\n1. Does using lower gas pressure shorten the time people spend in the recovery room after surgery?\n2. Does using lower gas pressure lead to less pain and reduce the need for pain medicine after surgery?",[131,132],"Robotic Surgery","Pneumoperitoneum",[134,135,136,137,138],"robotic surgery","low-pressure pneumoperitoneum","recovery time","pain","pneumoperitoneum","2026-08-18",{"date":60,"type":36},{"date":142,"type":36},"2026-07-30",{"date":144,"type":22},"2027-02",{"name":42,"class":43},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},"100641445","decision-support-tool-for-patients-with-advanced-breast-cancer-100641445","NCT07635147","Decision Support Tool for Patients With Advanced Breast Cancer","Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)","COAST","Inclusion Criteria:\n\n* Male or female 18 years and older\n* Diagnosis of Stage IV breast cancer\n* English, Spanish or Mandarin speaking\n\nExclusion Criteria:\n\n* Early breast cancer\n* Individuals speaking languages other than English, Spanish, or Mandarin as their primary language",{"count":127,"type":22},[25],"The goal of this pilot study is to understand and improve the shared decision-making process between people with advanced breast cancer and their providers regarding their care and treatment. As part of this study, the researchers will evaluate a decision support tool called COAST that was designed to support patients and providers in having meaningful conversations. The main questions it aims to answer are:\n\n1. Can the COAST tool improve the quality of communication between patients and their oncology providers?\n2. Is the COAST tool acceptable, appropriate, and easy to use at NYP-Weill Cornell Medicine, NYP-Brooklyn Methodist Hospital and NYP-Queens?\n\nParticipants will be asked to fill out two surveys: one before they use the COAST tool and another about 2 - 4 weeks later. Some patients will also be invited for an interview.",[158,159,160,161],"Breast Cancer Metastatic","Advanced Breast Cancer","Stage 4 Breast Cancer","Stage IV (Metastatic) Breast Cancer",[163,164,165,166],"Decision support tool","advanced breast cancer","communication","Treatment preferences",{"date":33,"type":36},{"date":169,"type":36},"2026-06-17",{"date":171,"type":22},"2028-02",{"name":42,"class":43},3,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":17,"sex":18,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":66},"100604212","technology-based-intervention-usability-and-pilot-testing-100604212","NCT07146581","Technology-Based Intervention Pilot Testing","Primary Care Screening and Intervention for Caregiving Assessment and Support for Patients With Dementia: Technology-Based Intervention Usability and Pilot Testing","SIRENS","Caregiver Inclusion Criteria\n\n* 21 years old or older\n* Provides care for a patient of Weill Cornell Medicine\u002FNewYork-Presbyterian who meets the following criteria: (pilot only)\n\n  * Patient is at least 65 years old\n  * Patient has diagnosed dementia\n  * Patient requires assistance with at least 1 ADL\n* Self-identifies as primary informal caregiver for an older adult\n* Provides direct care (may include logistics, oversight, observation, as well as hands-on care, but must include at least some in-person assistance)\n* Can read and speak English at a 6th grade level or above\n* Not blind or deaf\n* No active plan to disengage from providing care to the older adult within the next year\n* Ability to travel to the COA or CABR for study activities and\u002For attend study session(s) virtually through Zoom on their personal device\n\nCaregiver Exclusion Criteria\n\n* Non-fluent English speaker\n* Hired caregiver\n* Provides care for a patient in hospice care\n* Too ill or weak to complete the interviews (per the interviewer)","21 Years",{"count":184,"type":22},40,[25],"This research project has three main goals:\n\n(1) To create a new screening tool that helps primary care doctors spot signs of neglect in older adults with dementia. (2) To design a support program that can be delivered both in person and through a mobile app on Android phones. (3) To run a clinical trial with three groups of participants to find out how effective the screening tool is on its own, and how effective it is when combined with the support program-compared to standard care.\n\nThis current phase of the project focuses on parts of goals 1 and 2, as described below.",[188,189,190],"Dementia","Elder Abuse","Elder Neglect",[192,193],"Older Adults","Technology","NOT_YET_RECRUITING",{"date":60,"type":36},{"date":197,"type":22},"2026-09-15",{"date":199,"type":22},"2026-12-31",{"name":42,"class":43},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":217,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":44},"100598123","improving-the-heart-health-of-home-health-aides-100598123","NCT07067398","Improving the Heart Health of Home Health Aides","Improving the Cardiovascular Health of Home Health Aides","VITAL","Inclusion Criteria\n\nHome Health Aide Participants\n\n* Currently working as a home health aide\n* Speak English or Spanish\n* ≥ 18 years of age\n* Have low CV Health as assessed by LE8 components made up by physical health measurements (blood pressure, BMI) and general self-reported health (physical activity, diet, smoking, sleep); calculated to be a score of 0-50 (the total score ranges from 0-100)\n\nPeer Coach Participants\n\n* Previously participated in and completed Peer Coach training as part of the prior LE8 study (WCM IRB #24-11028134), or are members of the Weill Cornell Medicine study team who are trained in delivering the intervention.\n* Speak English or Spanish\n\nExclusion Criteria:\n\nHome Health Aide Participants\n\n* Less than 1 year of job experience as a home health aide\n* Does not possess a smartphone\n* Gotten dizzy before with a finger stick blood sugar\u002Fcholesterol test\n* Have a history of syncope with a finger stick blood sugar\u002Fcholesterol test\n\nPeer Coach Participants\n\n* Speak a language other than English or Spanish\n* Did not complete Peer Coach training as part of the prior LE8 study (WCM IRB #24-11028134), or are not members of the Weill Cornell Medicine study team who are trained in delivering the intervention.",{"count":184,"type":22},[25],"The goal of this early-stage study is to support the heart health of home health aides, a workforce that provides care for adults at home but whose own health has been historically poor. To do this, the study will use Life's Essential 8 (LE8), a program developed by the American Heart Association (AHA) that promotes cardiovascular wellness through education and lifestyle changes. The program has been adapted specifically for home health aides and will be delivered by trained \"peer coaches,\" who are fellow home health aides who will help guide participants through the program.\n\nThe main questions the study aims to answer are:\n\n* Will the LE8 intervention, which provides cardiovascular health education and support with positive thinking, be used by home health aides and do they like it?\n* Does the LE8 intervention actually improve home health aides' cardiovascular health after the intervention's conclusion compared to baseline?\n\nParticipants will be paired with a trained peer coach and take part in the 10-week program over the course of 6 months. The program includes support for healthy behaviors and positive thinking, with the goal of making lasting improvements in cardiovascular health.",[213,214,215,216],"Cardiovascular","Cardiovascular (CV) Risk","Cardiovascular Disease (CVD) Risk Factors","Cardiovascular Health",[218,219,220],"cardiovascular health intervention","home health aide","peer coaching",{"date":60,"type":36},{"date":223,"type":36},"2025-09-09",{"date":225,"type":22},"2026-10",{"name":42,"class":43},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":244,"locationsCount":245},"100550228","impact-of-biosynthetic-mesh-on-paraesophageal-hernia-repair-100550228","NCT06444347","Impact of Biosynthetic Mesh on Paraesophageal Hernia Repair","The Impact of Biosynthetic Mesh on Paraesophageal Hernia Repair in Robotic Anti-Reflux Surgery: A Multi-Institutional Randomized Trial","Inclusion Criteria:\n\n* Documented diagnosis of gastroesophageal reflux disease\n* Adults aged 18 years or older\n* English speaking\n* Subject is planned to undergo surgery for reflux disease\n\nExclusion Criteria:\n\n* Physician deems the subject is unable to complete the study due to documented dementia.\n* Subject is undergoing emergent surgery.\n* Pregnancy\n* Patient has known allergy to tetracycline hydrochloride or kanamycin sulfate",{"count":235,"type":22},200,[25],"The aim of this study is to find out if using a certain kind of mesh can reduce the chances of hiatal hernias coming back after anti-reflux surgery. Participants undergoing antireflux surgery will be assigned to one of two groups, a group that has surgery with mesh, or a group that has surgery without mesh.",[239],"Hiatal Hernia",{"date":33,"type":36},{"date":242,"type":36},"2024-06-10",{"date":64,"type":22},{"name":42,"class":43},6,{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":269},"100537230","optimizing-surgical-decisions-in-young-adults-with-breast-cancer-100537230","NCT06275126","Optimizing Surgical Decisions in Young Adults With Breast Cancer","CONSYDER","Inclusion Criteria:\n\n* Female aged 18-44\n* New diagnosis of Stage 0, 1, 2, or 3 unilateral breast cancer\n* English or Spanish speaking\n\nExclusion Criteria:\n\n* Diagnosis of de novo Stage 4 breast cancer\n* Recurrent early-stage breast cancer\n* Bilateral breast cancer","44 Years",{"count":255,"type":22},800,[25],"The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions.\n\nParticipants will complete surveys approximately within 1 week of the surgical consult and approximately 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients\u002Fsurgeons will also have their surgical consultation audio-recorded.",[259,260,261,262],"Breast Cancer Stage 0","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",{"date":33,"type":36},{"date":265,"type":36},"2024-03-13",{"date":267,"type":22},"2027-08-31",{"name":42,"class":43},4,{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":66},"100537186","phase-3-testing-the-role-of-anti-fungal-therapy-in-improving-the-response-to-therapies-for-crohns-disease-100537186","NCT06274554","Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's Disease","FUN-CD","Inclusion Criteria:\n\n1. Patients at least 18 years old\n2. Patients with mild to moderate Crohn's disease as defined by CDAI score of 150-450\n\nExclusion Criteria:\n\n1. Antifungal usage within one month prior to initiation of blinded fluconazole usage\n2. Known allergy to fluconazole\n3. Patients with known hepatic disease, cirrhosis, or with elevated liver biochemistries (e.g., transaminase(s) \\>3X upper limit of normal (ULN), and\u002For bilirubin levels \\>1.5X ULN (with exception of confirmed Gilbert's disease) at baseline\n4. Patients taking any medications judged by clinical provider to interact with fluconazole and are known contraindications (refer to section 2.2) and cause serious adverse events, including but not limited to death, cardiac events, serious cardiac dysrhythmias, and prolongation of QTc\n5. Pregnant or lactating women\n6. Severe Crohn's disease defined by a PRO-2 score ≥ 34 or imminent need for surgery, or deemed not medically fit by physician\n7. Patient with symptomatic stricturing\n8. Patient with pouchitis or an ostomy\n9. Patients with known, active fungal infection(s) since these patients would require particular, standard-of-care monitoring and treatment, which may include intravenous and\u002For prolonged courses of fluconazole or other therapies.\n10. Patients with hypokalemia, or advanced cardiac failure\n11. Patients with renal insufficiency",{"count":279,"type":22},120,[281],"PHASE3","The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to start or are currently undergoing standard of care treatment and plan to dose-escalate an IL-23 therapy for their Crohn's disease.\n\nThe main question it aims to assess is whether or not patient response to IL-23 therapies improve when simultaneously treated with fluconazole.",[284,285],"Crohn's Disease","Inflammatory Bowel Diseases",[287,288],"Fluconazole","IL-23",{"date":60,"type":36},{"date":291,"type":36},"2024-10-04",{"date":293,"type":22},"2029-12",{"name":42,"class":43},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":17,"sex":18,"minAge":302,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":173},"100501598","center-for-research-and-education-on-aging-and-technology-enhancement---create-v---project-1-100501598","NCT05811338","Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1","Center for Research and Education on Aging and Technology Enhancement - CREATE V","Inclusion Criteria:\n\n* 65+ years of age\n* Able to read English at the 6th grade level\n* Have 20\u002F60 vision with or without correction.\n\nExclusion Criteria:\n\n* Blind or have visual impairments that limit their ability to view the technology.\n* Deaf or have hearing impairments that limit their ability to answer telephone queries.\n* Have a life-limiting\u002Fterminal illness\n* Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand\n* Chronic neck pain\u002Finjury that might make the headset uncomfortable","60 Years",{"count":304,"type":22},108,[25],"Project 1: The goal of this research project is to examine usability and acceptance of virtual reality (VR) applications and their efficacy with older adults. This highly innovative cross-site Stage 1 Intervention Development Project (NIH (National Institutes of Health) Stage Model) will apply the CREATE systematic approach to the design and evaluation of an immersive VR program, Cognitive Activity Social Technology (CAST), for older adults. The program will provide a suite of virtual cognitive, social and activity engagement applications; and allow for virtual interactions.",[308],"Mild Cognitive Impairment",[193],{"date":60,"type":36},{"date":312,"type":22},"2026-10-31",{"date":314,"type":22},"2027-05-31",{"name":42,"class":43},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":327,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":66},"100478220","phase-2-a-digital-intervention-for-post-stroke-depression-and-executive-dysfunction-100478220","NCT05507138","A Digital Intervention for Post-Stroke Depression and Executive Dysfunction","Efficacy and Target Engagement of a Digital Intervention to Improve Depression and Executive Dysfunction After Stroke","Inclusion Criteria:\n\n* first-time stroke that occurred 6 months or more prior to study initiation\n* executive dysfunction as defined by a score of less than 1 standard deviation below age-adjusted normative score on at least one test of executive function in the screening assessment\n* diagnosis of Major Depressive Episode assessed by the Structured Clinical Interview for the DSM-5 (SCID).\n* at least moderate depressive symptoms as defined by Montgomery Asberg Depression Rating Scale ≥ 18\n* motor function sufficient to operate an iPad and use a pen, based on self-report and observation\n* if treated with an antidepressant medication, must be on a stable dose for a minimum of 8 weeks at the time of study enrollment.\n* able to adhere to all testing and study requirements and willingness to participate in the full study duration\n\nExclusion Criteria:\n\n* receptive aphasia as determined by a score of 2 or 3 on the NIH Stroke Scale \\[NIHSS\\] item 9 (\"Best Language\")\n* dysarthria that makes speech unintelligible (score of 2 on NIHSS item #10)\n* severe visual impairment or hemispatial neglect (score of 3 on NIHSS item #3 or score of 2 on NIHSS item #11)\n* patient already enrolled in ongoing concurrent cognitive rehabilitation (note that if a subject is already enrolled in psychotherapy, this will not be grounds for exclusion)\n* non-fluency in English\n* presence of or history of significant neurologic or neurodegenerative disorder other than stroke\n* presence of dementia based on dependence in basic ADLs due to cognitive deficits\n* history of psychosis or mania (evaluated using the SCID).\n* active suicide ideation (assessed via the Columbia Suicide Severity Rating Scale)\n* severe executive dysfunction (based on clinical judgment during screening evaluation) precluding use of the iPad\n* severe depression-even in the absence of active suicidal ideation-based on the screening evaluation and clinical judgment of the PI, which warrants a higher level of care and\u002For immediate referral to psychiatric services.\n* pregnancy\n* any other clinical or medical reason in the PI's initial screening evaluation that suggests the study is not appropriate for the participant.","50 Years","79 Years",{"count":326,"type":22},70,[328],"PHASE2","Individuals with stroke commonly experience both depression and cognitive difficulties. The goal of this study is to evaluate the efficacy of a treatment that combines a digital therapeutic (an iPad-based cognitive training program) with learning cognitive strategies. The hypotheses are that this treatment will improve cognitive skills, depression symptoms, daily function, and brain connectivity. In the short-term, the findings will inform the efficacy of the intervention and in the long-term, may support the use of the intervention to improve co-occurring cognitive and mood difficulties after stroke.",[331,332,333],"Executive Dysfunction","Depression","Stroke",{"date":60,"type":36},{"date":336,"type":36},"2023-03-01",{"date":338,"type":22},"2027-09-30",{"name":42,"class":43},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":365},"100302428","randomization-of-single-vs-multiple-arterial-grafts-100302428","NCT03217006","Randomization of Single vs Multiple Arterial Grafts","Randomized Comparison of the Clinical Outcome of Single Versus Multiple Arterial Grafts: the ROMA Trial","ROMA","Inclusion Criteria:\n\n* Primary isolated CABG patients with disease of the left main coronary artery and\u002For of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.\n\nExclusion Criteria:\n\n* Age \\> 70 years\n* Single graft\n* Emergency operation\n* Evolving myocardial infarction within 48 hours of surgery\n* Left ventricular ejection fraction of \\\u003C 35%\n* Any concomitant cardiac or non-cardiac procedure\n* Previous cardiac surgery\n* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduce life expectancy to less than 5 years.\n* Inability to use the saphenous vein or to use both radial and right internal thoracic arteries\n* Anticipated need for coronary thrombo-endarterectomy\n* Planned hybrid revascularization","70 Years",{"count":350,"type":22},4300,[25],"The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and\u002For repeat revascularization. The secondary hypothesis is that in patients undergoing primary isolated non-emergent CABG, the use of two or more arterial grafts compared to a single arterial graft is associated with improved survival.\n\nProspective event-driven unblinded randomized multicenter trial of at least 4,300 subjects enrolled in at least 25 international centers. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG). Patients will be randomized in a 1:1 fashion between the two groups. Permuted block randomization with random blocks stratified by the center and the type of second arterial graft will be used to provide treatment distribution in equal proportion.",[354,85],"Coronary Artery Disease",[356,357,358],"coronary artery bypass surgery","multiple arterial graft","radial artery graft",{"date":60,"type":36},{"date":361,"type":36},"2018-01-07",{"date":363,"type":22},"2030-12-31",{"name":42,"class":43},59,{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":17,"sex":52,"minAge":19,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":269},"100528998","trial-of-ovarian-vein-and-pelvic-vein-embolization-in-women-with-chronic-pelvic-pain-and-pelvic-varices-100528998","NCT06168058","Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices","Randomized Controlled, Single-Blinded, Parallel-Group Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices (EMBOLIZE) Trial","EMBOLIZE","Inclusion Criteria:\n\n1. Presence of venous origin chronic pelvic pain for greater than 6 months (VAS ≥7 as determined by 4 consecutive weeks of baseline self-assessments) despite non-vascular therapy as delineated by the following criteria:\n\n   * Pain exacerbated by walking, standing or lifting\n   * Symptoms are at least partially alleviated by lying down\n   * Prolonged post-coital ache\n   * Absence of non-venous origin CPP as determined by Gynecology examination\n2. Symptoms-Varices-Pathophysiology Classification18 including of one of the following:\n\n   •S2V2PBGV,R,NT, S2V2PRGV,R,NT , S2V2PLGV,R,NT, with or without S2V2 PBIIV,R,NT, S2V2 PLIIV,R,NT, S2V2 PRIIV,R,NT\n3. CT, TAUS and diagnostic venography (if needed) imaging review for pelvic venous imaging factors\n\n   * Left or right ovarian vein diameter greater than or equal to 6 mm as documented by TAUS or CT\n   * Presence of intrabdominal\u002Fpelvic varices as documented by TAUS or CT (≥1 veins, \\>5 mm diameter)\n   * Presence of venous reflux in ovarian and\u002For internal iliac veins without evidence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* Female \\\u003C18 years of age\n* Pregnancy (positive pregnancy test)\n* Female subject who plans to become pregnant during study period\n* Female subject who is actively breastfeeding\n* Patient who is post-menopausal or anovulatory with hormone suppression\n* History of prior hysterectomy\n* Prior ovarian vein embolization or ovarian vein ligation\n* Inability to tolerate endovascular procedure due to acute illness or general health\n* Planned simultaneous treatment with nerve blocks during the duration of the study\n* Laparoscopy or planned surgical intervention during the duration of the study\n* Known allergy to sclerosant, coil, stent or catheter components including nickel allergy\n* Any iliac vein stenosis determined identified by the investigator on pelvic DUS, CT venogram, and\u002For Catheter Venography and deemed significant for exclusion by study patient review committee.\n* Any renal vein stenosis with resultant renal hilar varices\u002Fcollaterals and lumbar collaterals identified by the investigator on pelvic DUS, CT venogram, and\u002For Diagnostic Venography and deemed significant for exclusion by study patient review committee.\n* Presence of isolated extra-pelvic vulvar and\u002For lower extremity varices without intrabdominal pelvic varices. Primary S3 categorization study exclusion.\n* Serious medical conditions that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, COPD, MI, CHF, etc.)\n* Severe allergy to iodinated or gadolinium-based contrast refractory to steroid premedication\n* Severe renal impairment (on chronic dialysis or estimated GFR \\\u003C30 mL\u002Fmin)\n* Hemoglobin \\\u003C8.0 g\u002FdL, uncorrectable INR \\>3.0 or platelet count \\\u003C75,000\u002Fmicroliter\n* Inability to provide informed consent or to comply with study assessments\n* Post thrombotic IVC, iliac or ovarian vein changes","75 Years",{"count":184,"type":22},[25],"The purpose of this study is to see if a randomized controlled trial of ovarian vein and pelvic vein embolization versus venography alone could determine outcomes for women with chronic pelvic pain and pelvic varicose veins.\n\nThe data gathered will assist in addressing changes in quality of life in patients who have ovarian\u002Fpelvic vein embolization versus no embolization.",[379,380,381,382,383],"Chronic Pelvic Pain Syndrome","Pelvic Pain","Pelvic Varices","Pelvic Congestive Syndrome","Pelvic Pain Syndrome","2026-08-17",{"date":60,"type":36},{"date":387,"type":36},"2025-10-29",{"date":389,"type":22},"2027-06",{"name":42,"class":43},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":44},"100521563","improving-the-mental-health-of-home-health-aides-100521563","NCT06071221","Improving the Mental Health of Home Health Aides","Improving the Mental Health of Home Health Aides: A Pilot Randomized Controlled Trial","MINDSET","Inclusion Criteria:\n\n* Currently working as a home health aide\n* Speak English or Spanish\n* ≥ 18 years of age\n* Have mild depressive symptoms (Personal Health Questionnaire 8-item \\[PHQ8\\] scale ≥ 5 points), or other risk factors for poor mental health as assessed by the following domains including stress (Cohen's Perceived Stress 4-item scale \\[PSS4\\] ≥5) or loneliness (≥6 on the 3-item UCLA Loneliness scale).\n\nExclusion Criteria:\n\n* Speak a language other than English or Spanish\n* Less than 1 year of job experience as a home health aide",{"count":127,"type":22},[25],"The goal of this study is to improve the mental health of home health aides, a workforce that provides care for adults at home but whose own health has been historically poor. The main questions the study aims to answer are:\n\n* Will a health program called Living Healthy, which provides health education and support with positive thinking, be used by home health aides and do they like it?\n* Does Living Healthy actually improve home health aides' mood compared to what they usually do to take care of themselves?\n\nParticipants in the study will get an 8-week health program called Living Healthy over 3 months. Some of the participants will also have a 'peer coach' who is another home health aide who's been trained to help them with the program and learn some ways to feel better.\n\nThe study will compare the experiences of home health aides who get Living Healthy plus a peer coach with those who only get the Living Healthy program.",[403],"Mental Health Issue",[405,219,406,220,407],"behavioral health intervention","depressive symptoms","stress",{"date":60,"type":36},{"date":410,"type":36},"2025-01-27",{"date":389,"type":22},{"name":42,"class":43},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":302,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":66},"100445527","a-primary-care-based-psychosocial-intervention-to-improve-cognitive--depression-outcomes-in-older-adults-with-mci--early-stage-ad-100445527","NCT05081596","A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD","PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults With MCI and Early Stage AD","PATH-Pain","Inclusion Criteria:\n\n* Age ≥ 60 years old\n* MCI or early stage probable or possible AD diagnosis (as defined by Albert et al or McKhann et al) al). Patients will have at least mild cognitive deficits defined by 16 ≤ MoCA ≤ 25.\n* Montgomery Asberg Depression Rating Scale (MADRS)\\[55\\] total ≥ 5, which reflects at least some mild depressive symptoms.\n* Participants will be off antidepressants, cholinesterase inhibitors or memantine or on a stable dosage for at least 12 weeks.\n* Chronic pain (neuropathic, nociceptive or mixed disorders): presence of pain on most days for at least 3 months and average pain intensity score \\>=4.\n* Clinical Dementia Rating 0.5 ≤ (CDR) ≤ 1.\n* Participant will have capacity to consent.\n* Participation of a study partner (e.g. caregiver\u002Ffamily member\u002Fsignificant other) is required.\n\nExclusion Criteria:\n\n* Deemed to have a significant suicide risk as assessed by site PI and clinical team.\n* Deemed too unstable medically or neurologically to safely enroll in a research trial.\n* Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy.\n* Requiring psychiatric hospitalization at baseline for safety.\n* Lack of English fluency.",{"count":127,"type":22},[25],"The purpose of the study is to examine the effect of Problem Adaptation Therapy for Pain (PATH-Pain) on cognitive functioning, depression and pain-related disability in 100 older adults with cognitive impairment, chronic pain, and depression. The study will test if PATH-Pain has better cognitive, affective, and functional outcomes than Attention Control Usual Care.",[332,425,426],"Pain","Cognitive Impairment",[192,308,428],"Early Stage Alzheimer's Disease",{"date":60,"type":36},{"date":431,"type":36},"2022-06-03",{"date":433,"type":22},"2027-07-31",{"name":42,"class":43},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":374,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":444,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":66},"100652511","app-mnt-app-enhanced-medical-nutrition-therapy-on-glycemic-outcomes-and-quality-of-life-100652511","NCT07773779","APP-MNT: App-Enhanced Medical Nutrition Therapy on Glycemic Outcomes and Quality of Life","App-MNT","Inclusion Criteria:\n\n* Male or female 18-75 years of age.\n* Documentation of a T1D or T2D diagnosis.\n* A1C of 6.5 or greater.\n* Access to a compatible smartphone.\n* Using a Dexcom continuous glucose monitoring device (due to compatibility with Undermyfork app) for at least 1 month with an active time of at least 70% within the last 14 days.\n\nExclusion Criteria:\n\n* Heart failure.\n* Advanced kidney disease.\n* Severe cognitive or psychological disabilities.\n* Depression.\n* Pregnant or breastfeeding.",{"count":443,"type":22},52,[25],"The purpose of the study is to see if using a diabetes app along with nutrition counseling from a registered dietitian nutritionist can help improve blood sugars and cholesterol levels, quality of life, physical activity, and food and beverage choices.",[447],"Diabetes (Insulin-requiring, Type 1 or Type 2)",[449,450,451,452,453,454,455,456],"Diabetes type 1","Diabetes type 2","Nutrition app","Medical Nutrition Therapy (MNT)","MNT","CGM","Continuous Glucose Monitor","Personalized Nutrition","2026-08-14",{"date":33,"type":36},{"date":460,"type":36},"2026-07-29",{"date":433,"type":22},{"name":42,"class":43},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":300,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":17,"sex":18,"minAge":302,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":477,"leadSponsor":478,"locationsCount":173},"100630287","center-for-research-and-education-on-aging-and-technology-enhancement---create-v---project-2-100630287","NCT07485712","Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2","Inclusion Criteria:\n\n* 62+ years of age\n* Able to read English at the 6th grade level\n* Have 20\u002F60 vision with or without correction.\n* Clinical diagnosis of mild cognitive impairment (MCI)\n* Subjective cognitive complaints\n* Evidence by clinical evaluation\n* Clinical Dementia Rating Global scale of 0.5-2.0\n* Probable MCI\n* Montreal Cognitive Assessment (MoCA) score of 18-26\n* No major Instrumental activities of daily living (IADL) impairments\n* Geriatric Depression Scale of 4 or Below\n* No diagnosis of dementia\n\nExclusion Criteria:\n\n* Blind or have visual impairments that limit their ability to view the technology.\n* Deaf or have hearing impairments that limit their ability to answer telephone queries.\n* Have a life-limiting\u002Fterminal illness\n* Severe motor impairment (e.g., severe tremors or debilitating arthritis in their hands) that impairs ability to speak or use dominant hand\n* Cognitive impairment (MOCA ≤ 25)",{"count":279,"type":22},[25],"The goal of this Stage 1 (NIH Stage Model) Intervention Development cross-site project is to develop, using a user-centered design approach, and evaluate an innovative intelligent adaptive software package aimed at providing cognitive and social support and engagement to older adults with mild cognitive impairment (MCI). The system will be designed to adapt to the needs and abilities of the user. The investigator's goal is to develop a unique and highly innovative technology tool that can provide adaptive support to aging individuals with MCI, even as cognition might deteriorate further. Speech data collected as part of an embedded reminiscence feature will advance fundamental knowledge of how speech and language production data might serve as an early indicator of cognitive decline.",[308],[193],"2026-08-13",{"date":384,"type":36},{"date":312,"type":22},{"date":314,"type":22},{"name":42,"class":43},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":52,"minAge":487,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":497,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":44},"100651725","ovarian-cancer-liquid-biopsy-for-early-assessment--detection-in-individuals-with-brca12-pathogenic-variants-100651725","NCT07764744","Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1\u002F2 Pathogenic Variants","Ovarian Cancer Liquid Biopsy for Early Assessment & Detection (OC-LEAD)","OC-LEAD","Inclusion Criteria:\n\nCohort A participants must meet all of the following criteria:\n\n1. Age ≥ 35 years (based on current National Comprehensive Cancer Network guidelines35 for risk-reducing gynecologic surgery) with no upper age limit\n2. Confirmed germline PV or likely PV in the BRCA1 or BRCA2 genes, documented by CLIA-certified genetic testing.\n3. Scheduled to undergo risk-reducing gynecologic surgery (salpingo-oophorectomy or salpingectomy with or without hysterectomy) at the study site.\n4. Willing and able to provide informed consent in English This initial phase is limited to English-speaking participants. This limitation is due to feasibility considerations for initial qualitative instrument validation; future phases will incorporate translated materials\n\n   Cohort B participants must meet all of the following criteria:\n5. Age ≥ 35 years with no upper age limit.\n6. STIC lesion previously identified on surgical pathology within the prior 10 years.\n7. Willing and able to undergo baseline and annual research blood draws for up to 10 years following STIC lesion diagnosis.\n8. Willing and able to provide informed consent in English\n\nExclusion Criteria:\n\nCohort A:\n\n1. Pregnant or breastfeeding at the time of enrollment.\n2. Prior removal of bilateral fallopian tubes and\u002For bilateral ovaries.\n3. Active diagnosis of cancer.\n4. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent.\n5. Patients with a history of cancer are eligible when \\> 2 years no evidence of disease.\n6. Inability to provide informed consent.\n7. Concurrent participation in another interventional trial that may confound study outcomes.\n\nCohort B:\n\n1. Pregnant or breastfeeding at the time of enrollment.\n2. Active diagnosis of cancer.\n3. Prior or active diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer at the time of consent (prior STIC lesion is NOT a contraindication to enrollment).\n4. Patients with a history of cancer are eligible when \\> 2 years no evidence of disease.\n5. Inability to provide informed consent.\n6. Concurrent participation in another interventional trial that may confound study outcomes.","35 Years",{"count":326,"type":22},[25],"The goal of this clinical study is to evaluate the feasibility and acceptability of the Galleri multi-cancer early detection blood test in people with BRCA1 or BRCA2 gene changes who are at high risk for ovarian cancer. The study will also explore how well the test detects ovarian cancer or related precancerous conditions.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to incorporate the Galleri blood test into the care of people at high \\* risk for ovarian cancer?\n* Is the Galleri blood test acceptable to participants?\n* How well does the Galleri blood test identify ovarian cancer or related precancerous conditions?\n\nParticipants will:\n\n* Receive the Galleri blood test.\n* Complete questionnaires about their experience with the test.\n* Some participants will also complete an interview about their experiences and preferences.\n* Continue with their planned standard medical care, including surgery or follow-up visits, as appropriate.",[492,493,494,495,496],"Ovarian Neoplasms","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation","Serous Tubal Intraepithelial Carcinoma","Early Detection of Ovarian Cancer",[498,499,500,501,502,503,504,505,506,507,508,509,510],"Ovarian cancer","Liquid biopsy","Galleri","Multi-cancer early detection","BRCA1","BRCA2","Hereditary breast and ovarian cancer syndrome","Serous tubal intraepithelial carcinoma (STIC)","Risk-reducing salpingo-oophorectomy","Early cancer detection","Hereditary cancer","Cancer screening","Implementation science","2026-08-10",{"date":457,"type":36},{"date":514,"type":22},"2026-08",{"date":516,"type":22},"2039-07",{"name":42,"class":43},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":52,"minAge":525,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":23,"phases":528,"briefSummary":529,"conditions":530,"keywords":532,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":539,"leadSponsor":541,"locationsCount":66},"100616083","behavioral-pain-intervention-for-older-cancer-patients-100616083","NCT07300995","Behavioral Pain Intervention for Older Cancer Patients","Brief Pain Coping Skills Training for Older Women With Breast Cancer and Pain: An Efficacy-Effectiveness Randomized Controlled Trial","Inclusion Criteria:\n\n* Receiving cancer care at a Duke Cancer Network (DCN) clinic\n* Stage I-IV breast cancer\n* Self-reported pain on at least 10 days in the last month and pain rating of worst pain of 4 or greater on a 0-10 scale in the last week\n* Biologically female\n* Greater than or equal to 55 years old\n* Ability to speak and read English\n* Hearing and vision that allows for successful completion of videoconferencing and phone session\n\nExclusion Criteria:\n\n* Participation in the last 6 months in a pain coping skills training program","55 Years",{"count":527,"type":22},168,[25],"This randomized controlled trial examines a 1-session, telehealth pain coping skills training (PCST) protocol with five 15-minute maintenance calls (Brief PCST-Community) adapted for women with breast cancer in medically underserved areas. Pain, health-related quality of life, and self-efficacy for pain management will be assessed at baseline and 10 and 15 weeks later.",[531],"Breast Cancer",[533,137,534,535],"cancer","coping","symptom management",{"date":537,"type":36},"2026-08-12",{"date":169,"type":36},{"date":540,"type":22},"2027-06-01",{"name":42,"class":43},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":550,"maxAge":551,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":553,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":44},"100650475","digital-mindfulness-meditation-in-adolescents-with-atopic-dermatitis-100650475","NCT07746427","Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis","Outcomes of a Digital Mindfulness Meditation App-Based Intervention in Adolescents With Moderate to Severe Atopic Dermatitis (MIND-AD)","MIND-AD","Inclusion Criteria\n\n* Adolescents age 12-17 years.\n* Atopic dermatitis refractory to standard topical treatment including topical steroids or topical calcineurin inhibitors.\n* Moderate to severe atopic dermatitis via PO-SCORAD score on enrollment.\n\nExclusion Criteria\n\n* Started on a biologic agent (i.e. dupxient) within the past 3 months.\n* Mild atopic dermatitis via PO-SCORAD score on enrollment.","12 Years","17 Years",{"count":184,"type":22},[25],"Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients. The investigators hypothesize that regular use of a digital mindfulness meditation app will improve disease control and quality of life in adolescents with moderate to severe atopic dermatitis based on validated survey measures.",[556,557],"Atopic Dermatitis","Eczema",[559,560,561],"Meditation","mindfulness","digital health","2026-08-06",{"date":564,"type":36},"2026-08-07",{"date":566,"type":22},"2026-08-15",{"date":568,"type":22},"2028-07",{"name":42,"class":43},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":180,"eligibilityCriteria":576,"healthyVolunteers":17,"sex":18,"minAge":182,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":589,"locationsCount":66},"100651208","primary-care-screening-and-intervention-for-patients-with-dementia-and-caregivers-100651208","NCT07758738","Primary Care Screening and Intervention for Patients With Dementia and Caregivers","Primary Care Screening and Intervention for Caregiving Assessment and Support for Patients With Dementia: Randomized Controlled Trial","Primary care provider Inclusion Criteria • Active PCP who may be a physician or nurse practitioner seeing adult primary care patients with dementia at: Weill Cornell Medicine\n\nPrimary care provider Exclusion Criteria\n\n• Not a PCP of older adults with dementia who may be at risk of being neglected.\n\nOlder Adult Inclusion Criteria:\n\n* Aged ≥ 60 years\n* Community-dwelling\n* Patient of WCM\u002FNYP\n* Has diagnosis of dementia (based on medical records prior to enrollment)\n* Requires assistance with at least 1 ADL\n* Able to travel to a WCM\u002FNYP clinic for study activities\n* Has informal (either unpaid or CDPAP) caregiver who provides ≥8 hours weekly\n* Not already known to be experiencing neglect from caregiver\n\nOlder Adult Exclusion Criteria:\n\n* In hospice\n* Decision has already been made to re-locate to an institution (including long-term care skilled nursing facilities)\n\nCaregiver Inclusion Criteria:\n\n* Age ≥ 21 years\n* Living with or near the older adult\n* Self-identifies as a caregiver for the older adult\n* Provides ≥ 8 hours per week of direct care (may include logistics, oversight, observation, as well as hands-on care, but must include at least some in-person assistance)\n* Able to travel to a WCM\u002FNYP clinic for study activities or participate in study activities virtually through Zoom on their personal device\n* Not a professional caregiver, does not receive direct payment in return for care (unless through CDPAP)\n* Can read and speak English at a 6th grade level\n* No active plan to disengage from providing care to older adult within the next year\n\nCaregiver Exclusion Criteria:\n\n* Unable to read and speak English at a 6th grade level\n* Hired\u002Fpaid professional caregiver\n* Is blind or deaf\n* Active plan to disengage from providing care to older adult within the next year",{"count":578,"type":22},774,[25],"The goal of this clinical trial is to evaluate the impact of screening for elder neglect in older adults with dementia in primary care settings and the impact of an intervention for caregivers of older adults with dementia.\n\nThe hypothesis of the study are:\n\n* Neglect screening in primary care will have a positive impact on outcomes including a decrease in presence of neglect at 6 months and other patient and caregiver outcomes\n* Neglect screening paired with a caregiving intervention will have a greater impact on these outcomes than screening alone\n\nResearchers will compare three groups of participants to find out how effective the screening tool is on its own, and how effective it is when combined with the support program, compared to standard care.\n\nParticipants will be asked to:\n\n* attend primary care clinic visits\n* complete questionnaires\n* participate in the intervention\n* participate in a semi-structured interview",[188,189,582],"Elder Mistreatment","2026-08-05",{"date":585,"type":36},"2026-08-11",{"date":587,"type":22},"2026-11-01",{"date":433,"type":22},{"name":42,"class":43},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":605,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":44},"100577585","phase-2-pain-reprocessing-therapy-in-post-operative-knee-pain-100577585","NCT06800209","Pain Reprocessing Therapy in Post-Operative Knee Pain","Efficacy and Mechanisms of Pain Reprocessing Therapy in Chronic Post-Operative Knee Pain","REJOICE","Inclusion Criteria:\n\n* Patients are deemed eligible at 3 months post-operatively if: The patient completed a primary knee replacement \\[surgery completed without complication and patient exhibits full mechanical joint function, as determined by the treating physician (good range of motion, stability, and wound healing; absence of swelling)\\] and patient reports last week average knee pain ≥ 4 of 20 and at least two questions rated 'moderate' on A 12-item shortened version (ShortMAC) of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).\n* Reported pre-operative chronic knee pain of at least 6 months duration prior to surgery\n* The procedure was a primary (not a revision) knee replacement\n* Proficient in English\n\nExclusion Criteria:\n\n* Patients who are not willing to participate in a telehealth visit.\n* Patients with pre-op chronic pain but who do not have post-operative pain after the three month time period.\n* Active suicidal ideation with intent, recent history of suicide attempt, or self-harm behaviors within the past 5 years (including non-suicidal self-harm).\n* Recent history of inpatient psychiatric hospitalization within the past 5 years.\n* Active, current psychosis or mania.\n* Active, current substance abuse, or problems with substance abuse within the past 2 years.\n* Instability in living conditions or major interfering life events:\n\n  * Major surgery or other major medical event planned in coming 6 months.\n  * Uncertain whether they will have suitable conditions for telehealth appointments over the next 2 months, including access to a computer or tablet, reliable high-speed internet, and a quiet, comfortable room that is consistently available.\n  * Major, interfering changes in employment or housing anticipated over the next 6 months.\n* Neurological conditions (e.g., Alzheimer's, dementia, mild cognitive impairment, Huntington's disease, multiple sclerosis, cerebral palsy). This will be case-by-case decision made by PI to determine if the condition may interfere with treatment and warrant exclusion.\n* Self-reported diagnosis of an autoimmune disease (e.g., rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus, polymyositis, or another autoimmune disorder).\n* Currently or plan to be involved in lawsuits related to pain in next 6 months, currently or plan to apply for any disability payments related to the pain in next 6 months, or received legal settlement or other disability payments related to the pain over past 2 years.\n\nEEG Exclusion Criteria (patients can still be enrolled as long as they meet all other eligibility criteria; however, they will not undergo EEG testing):\n\n* Are unable or uncomfortable with completing a dry cap EEG.\n* Has had a history of abnormal EEGs.\n* Had bilateral TKA",{"count":599,"type":22},110,[328],"The goal of this clinical trial is to learn whether Pain Reprocessing Therapy (PRT) can help adults with knee pain after knee replacement surgery. The study is comparing PRT to usual care (the regular treatment people get after surgery) to see which works better for relieving pain.\n\nThe main questions the study aims to answer are:\n\n1. Does PRT help lower pain in people who have chronic knee pain after knee surgery?\n2. How do the effects of PRT compare with usual care in terms of pain relief and other factors such as anxiety, depression, and sleep?\n3. How does PRT impact the brain?\n\nParticipants will:\n\n1. Be randomly assigned to receive either PRT or usual care.\n2. Complete questionnaires about their pain and health.\n3. If in the PRT group, have eight weekly therapy sessions over video calls with a therapist.\n4. If interested, may also take part in an optional EEG test to measure brain activity related to pain.",[603,604],"Pain, Chronic","Knee Pain Chronic",[606,607,608,609,610,611,560,612,613],"chronic pain","Pain Reprocessing Therapy","knee pain","total knee replacement","Total Knee Arthroplasty","mind-body","TKA","PRT","2026-08-03",{"date":583,"type":36},{"date":617,"type":36},"2025-08-13",{"date":619,"type":22},"2028-09-29",{"name":42,"class":43},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":302,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":638,"locationsCount":66},"100567725","a-community-health-worker-led-program-for-chronic-pain-and-loneliness-in-older-adults-100567725","NCT06671925","A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults","Targeting Loneliness in the Context of Chronic Pain Self-Management: An Intervention for Older Adults Living in Rural Areas","Inclusion Criteria:\n\n* Age \\>= 60 years;\n* Have a mobile or landline phone;\n* Self-reported chronic musculoskeletal pain (pain in muscles or joints for \\>= 3 months, \\>=4 (0-10 scale) average pain level over last week, \\>=1 day\u002Fprevious 30 when pain made it difficult to do usual activities);\n* Self-reported loneliness (Feeling lonely \"some of the time\" or more often);\n* Able to converse comfortably in English.\n\nExclusion Criteria:\n\n* Serious acute illness or hospitalization in the last month;\n* Planned major surgery in the next three months that would interfere with program participation (e.g., knee or hip replacement);\n* Severe cognitive impairment or other severe physical or psychiatric disorder judged by study team to pose a significant barrier to participation.",{"count":629,"type":22},80,[25],"The goal of this clinical trial is to test a new community health worker-delivered program (Strengthening COnnections to Overcome Pain, or SCOOP) that teaches strategies for managing chronic pain and loneliness to older adults living in rural areas. The main questions it aims to answer are:\n\n1. Does participating in SCOOP result in less pain interference with daily life?\n2. Does participating in SCOOP result in decreased loneliness?\n3. What is the level of participant engagement in SCOOP? Researchers will compare people who have participated in SCOOP with people who have not participated in SCOOP to see if SCOOP is helpful in decreasing pain interference and loneliness.\n\nParticipants will:\n\n1. Watch brief videos teaching strategies to manage pain and boost social connections.\n2. Engage in up to 7 weekly coaching sessions with a community health worker.\n3. Complete two telephone interviews about health, mental health, and functioning: one at baseline, and one 2 months later.",[633],"Chronic Pain",{"date":583,"type":36},{"date":636,"type":36},"2026-01-27",{"date":314,"type":22},{"name":42,"class":43},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":646,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":194,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":667,"completionDateStruct":668,"leadSponsor":669,"locationsCount":66},"100650536","autologous-fat-grafting-for-the-treatment-of-chronic-tendinopathy-100650536","NCT07748793","Autologous Fat Grafting for the Treatment of Chronic Tendinopathy","MFAT","Inclusion Criteria\n\n1. Age 18-80 years.\n2. Tendinopathy at any tendon location (e.g., rotator cuff\u002Fsupraspinatus, lateral epicondyle, gluteal\u002Fhip, Achilles, patellar).\n3. Confirmed tendon pathology: pain at the tendon site for \\> 3 months AND pathology confirmed on ultrasound.\n4. Failure of conservative treatment (e.g., activity modification, physical therapy, NSAIDs, corticosteroid injection, and\u002For PRP) for at least 6 weeks.\n5. Able to provide informed consent and complete questionnaires in English.\n\nExclusion Criteria\n\n1. Full-thickness tendon tear.\n2. Prior surgery at the target tendon site.\n3. Injection or other intervention at the target tendon site within the prior 6 months.\n4. Pregnancy or breastfeeding.\n5. Active local or systemic infection, bleeding diathesis or anticoagulation precluding the procedure, or other condition that in the investigator's judgment makes participation unsafe.\n6. Moderate-to-high-grade arthritis in the adjacent joint.","80 Years",{"count":184,"type":22},[25],"The goal of this clinical trial is to learn whether a one-time injection of a person's own concentrated fat (micro-fragmented adipose tissue, or MFAT) can reduce pain and improve function in adults (ages 18-80) with chronic tendinopathy - tendon pain lasting more than 3 months (for example, in the shoulder, elbow, hip, knee, or Achilles) - that has not improved with usual treatments such as physical therapy, cortisone shots, or platelet-rich plasma.\n\nThe main questions it aims to answer are:\n\n* Does injecting a person's own concentrated fat into a painful tendon reduce tendon pain?\n* Does it improve how well the tendon works, how long does any improvement last, and is the procedure safe?\n\nThis is a single-group study, so there is no separate comparison group; each participant's pain, function, and ultrasound results after treatment are compared with their own measurements taken before treatment.\n\nParticipants will:\n\n* Have a one-time procedure in which a small amount of fat is removed from the abdomen by liposuction (under local numbing), concentrated, and injected into the painful tendon using ultrasound guidance.\n* Complete short pain and function questionnaires and have ultrasound imaging of the tendon at study visits.\n* Be followed for about 12 months, with a phone or video check-in 3-7 days after the procedure, a 2-week skin check of the fat-removal site, and visits at 6 weeks, 3 months, 6 months, and 12 months.",[651],"Chronic Tendinopathy",[653,644,654,655,656,657,658,659,660,661,662,663,664],"Micro-fragmented adipose tissue","autologous fat grafting","adipose-derived stem cells","regenerative medicine","orthobiologics","percutaneous tenotomy,","ultrasound-guided injection","chronic tendinopathy","tendinopathy","lateral epicondylitis","rotator cuff tendinopathy","Achilles tendinopathy","2026-07-31",{"date":562,"type":36},{"date":514,"type":22},{"date":568,"type":22},{"name":42,"class":43},""]